Gut Microbiome Diversity: Enterotypes, FMT & Antibiotics

Your Gut Hosts 100 Trillion Bacteria from Over 1,000 Species

The human gastrointestinal tract harbors approximately 100 trillion microorganisms — bacteria, archaea, fungi, and viruses — collectively called the gut microbiome. This community contains an estimated 3.3 million unique protein-coding genes, compared to the approximately 20,000 in the human genome. The collective metabolic capacity of the gut microbiome vastly exceeds what humans can accomplish biochemically alone: fermenting dietary fiber into short-chain fatty acids (butyrate, propionate, acetate) that fuel colonocytes and regulate immune function, synthesizing vitamins B12 and K2, metabolizing bile acids, and producing neuroactive compounds including serotonin precursors (95% of the body's serotonin is synthesized in the gut under microbiome influence). Understanding who lives in the gut — and how diversity relates to health — is one of the defining biological research questions of the 21st century.

Enterotypes: Bacteroides vs. Prevotella

A 2011 paper by Manimozhiyan Arumugam and colleagues in Nature proposed that human gut microbiomes cluster into three discrete "enterotypes" — stable compositional states driven by dominant bacterial genera:

The enterotype concept has been refined since 2011 — the boundaries are not as discrete as initially proposed, and many individuals fall between clusters. Subsequent analyses with larger cohorts found that Bacteroides and Prevotella abundance represents a continuum rather than two distinct states. Nevertheless, the Bacteroides-dominated vs. Prevotella-dominated axis remains a robust feature of gut microbiome population structure and is strongly associated with long-term dietary patterns. The Prevotella-dominated microbiome predominates in individuals from non-Western populations consuming traditional plant-rich diets in Africa, Southeast Asia, and rural South America. The Bacteroides-dominated profile is characteristic of industrialized, high-meat-consumption populations.

Diversity as a Health Proxy

Alpha diversity — the number of different species within an individual's microbiome — consistently emerges as a health-correlated metric. Higher alpha diversity is associated with:

• Lower risk of Clostridioides difficile infection (high diversity microbiomes are more resistant to colonization)
• Better glycemic control and lower type 2 diabetes risk (Sonnenburg lab, Stanford)
• Reduced inflammatory bowel disease severity
• Lower body mass index (BMI) in some cohort studies
• Healthier immune responses and lower systemic inflammation markers (CRP, IL-6)

The causal direction is not always established — it is unclear whether low diversity causes poor health outcomes or whether poor health drives microbiome depletion. The relationship is bidirectional in many cases. However, intervention studies (high-fiber diet trials, probiotic studies) that increase microbiome diversity tend to improve correlated health outcomes, supporting the hypothesis that diversity itself is beneficial rather than merely a marker of underlying health.

Antibiotic Disruption: Effects Lasting Two Years

Antibiotics kill bacteria without discriminating between pathogens and the commensal microbiome. A 2010 study by Dethlefsen and Relman at Stanford, published in PLOS Biology, followed three healthy individuals through two courses of ciprofloxacin. The microbiome changed dramatically within 3–4 days of antibiotic initiation — some taxa declining 10-fold to 100-fold. Recovery began after antibiotic cessation but was incomplete: after six months, the microbiomes had not returned to their baseline composition. After a second antibiotic course, recovery was slower and even more incomplete.

Longer-term studies show effects persisting beyond two years:

• A 2018 study in Cell (Suez et al., Weizmann Institute) found that probiotic supplementation after antibiotics actually delayed microbiome recovery — the standard probiotic strains colonized and blocked re-establishment of the original microbiome. Autologous fecal microbiota transplant (using the patient's own pre-antibiotic stool) restored the microbiome within days.
• Pediatric antibiotic exposure is particularly consequential. Children who received antibiotics in the first 6 months of life showed altered microbiome composition at age 3 that correlated with increased risk of asthma and obesity. The association persists in multiple independent cohorts.

Species most commonly depleted by broad-spectrum antibiotics and slowest to recover include Bifidobacterium, Lachnospiraceae family members, and Faecalibacterium prausnitzii — a major short-chain fatty acid producer. The depletion of these species reduces colonization resistance — the ability of the microbiome to prevent establishment of pathogens like C. difficile.

Fecal Microbiota Transplant: 90% C. diff Cure Rate

Clostridioides difficile (formerly Clostridium difficile, C. diff) infection affects approximately 500,000 Americans annually, causing severe, often life-threatening diarrhea, particularly after antibiotic treatment depletes colonization resistance. Standard antibiotic treatment (vancomycin, fidaxomicin) fails in 20–30% of patients, who experience recurrent infection. After multiple recurrences, cure rates with additional antibiotics drop below 30%.

Fecal microbiota transplant (FMT) — transferring stool from a healthy donor (screened for pathogens) into the gut of a C. diff patient via colonoscopy, enema, or oral capsule — achieves cure rates of 80–92% in recurrent C. diff patients across multiple randomized controlled trials. The mechanism: transferring thousands of microbial species from a healthy donor restores colonization resistance, outcompeting C. difficile. The 2013 Dutch trial by van Nood and colleagues (New England Journal of Medicine) demonstrated 81% cure rate with a single FMT infusion vs. 31% for vancomycin — results striking enough that the trial was stopped early by the safety board so control patients could receive FMT.

The FDA approved two commercial FMT products in 2022–2023:

• Rebyota (Ferring Pharmaceuticals) — FDA-approved November 2022 for recurrent C. diff; delivered rectally; contains microbiota from screened donors
• Vowst (Seres Therapeutics) — FDA-approved April 2023; oral capsules containing purified spores from donor stool; first oral microbiome-based therapy approved in the USA

Research is actively exploring FMT for conditions beyond C. diff: inflammatory bowel disease (clinical trials ongoing, modest efficacy demonstrated for ulcerative colitis), metabolic syndrome, autism spectrum disorder (preliminary), and Parkinson's disease (based on the gut-brain axis hypothesis). The therapeutic potential of the microbiome — and its manipulation through dietary, probiotic, and FMT interventions — is the subject of intense pharmaceutical and academic research that will define a significant portion of medicine over the next two decades.